Screening and the costs of treating colorectal cancer: some preliminary results

Tuck, Jaclyn; Walker, A. J.; Whynes, David K.; Pye, Geoffrey W.; Hardcastle, J. D.; Chamberlain, Jocelyn

doi:10.1016/s0033-3506(89)80050-2

Cited by 22 publications

(9 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2–9 In addition, management of this disease has changed in many areas, with shorter hospital stays, increasing use and range of adjuvant therapies and calls for more intensive follow up 10,11. Whynes et al examined the costs of hospital based care, publishing their findings in the BJC in 1993 3.…”

Section: Introductionmentioning

confidence: 99%

Hospital Costs of Colorectal Cancer Care

Macafee

West

Scholefield

et al. 2009

Clinical medicine. Oncology

Self Cite

View full text Add to dashboard Cite

Objective:In a hospital based setting, identify factors which influence the cost of colorectal cancer care?Design:Retrospective case note reviewSetting:Nottingham, United KingdomParticipants:227 patients treated for colorectal cancerMethods:Retrospective review of the hospital records provided the primary data for the costing study and included all CRC related resource consumption over the study period.Results:Of 700 people identified, 227 (32%) sets of hospital notes were reviewed. The median age of the study group was 70.3 (IQR 11.3) years and there were 128 (56%) males. At two years, there was a significant difference in costs between Dukes D cancers (£3641) and the other stages (£3776 Dukes A; £4921 Dukes B). Using univariate and multivariate regression, the year of diagnosis, Dukes stage of disease, intensive nursing care, stoma requirements and recurrent disease all significantly affected the total cost of care.Conclusions:CRC remains costly with no significant difference in costs if diagnosed before compared to after 1992. Very early and very late stage cancers remain the least costly stage of cancers to treat. Other significant effectors of hospital costs were the site of cancer (rectal), intensive nursing care, recurrent disease and the need for a stoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Hospital Costs of Colorectal Cancer Care

Macafee

West

Scholefield

et al. 2009

Clinical medicine. Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…A priori estimation of the relative importance of these cost items should guide the data collection (Turk el al., 1989). Sometimes, costs per diagnosis-related group (DRG) may be readily available (Munoz el al., 1989).…”

Section: Delerminalion Of Coslsmentioning

confidence: 99%

Economic evaluation of cancer treatments

Groot¹

1998

Anti-Cancer Drugs

View full text Add to dashboard Cite

“…Preliminary results suggest that overall hospital costs will be the same when comparing test groups and controls (21,22), but there will be an initial increase of costs. The total costs of a screening program are related to the age of participants compliance, positivity rate, intervals of screening, and methods of further examination in subjects with a positive test.…”

Section: Average Riskmentioning

confidence: 99%

Screening Guidelines for Colorectal Cancer

Kronborg

1992

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

Kronborg 0. Screening guidelines for colorectal cancer. Scand J Gastroenterol 1992;27 Suppl 192: 123-129. A review is given of methods and rcsults of screening for colorectal cancer in average-risk and high-risk groups. Possible methods are digital rectal exploration, endoscopic examination, barium enemas, faecal occult blood tests, tumour markers like carcinoembryonic antigen, Ca-19-9, and others, and gene markers. Final results of large randomized population studies with faecal occult blood tests are expected within the next few years, but it will probably be necessary to add flexible sigmoidoscopy to achieve a major reduction in mortality from colorectal cancer in average-risk persons. Recommendations for screening in high-risk groups are proposed, but strong support for these guidelines are still missing, an exception being first-degree relatives of individuals with familial adenomatous polyposis; the other highrisk groups include members of hereditary non-polyposis colorectal cancer families, relatives of patients with sporadic colorectal cancer, patients with colorectal adenomas. patients with previous colorectal cancer. and patients with inflammatory bowel disease.

show abstract

Screening and the costs of treating colorectal cancer: some preliminary results

Cited by 22 publications

References 3 publications

Hospital Costs of Colorectal Cancer Care

Hospital Costs of Colorectal Cancer Care

Economic evaluation of cancer treatments

Screening Guidelines for Colorectal Cancer

Contact Info

Product

Resources

About